Myconostica Ltd

develops and supplies molecular diagnostic products to
aid speedy, accurate diagnosis of life-threatening fungal infections in humans.

With recent advances in genomics and Real-Time PCR technology, rapid molecular
testing is now possible and highly desirable and can transform the ability of medics
to save both patients' lives and significant expenditure on hospitalization and drug treatment.

All developed countries have recorded steep increases in these blood-stream, respiratory and brain infections. Under-diagnosis and slow diagnosis with current methods available contribute to a high death rate.

We are a spin-out company of the University of Manchester, and a Partner Company
of Amphion Innovations plc. (Amphion, AIM: AMP, develops and operates companies
in the life sciences and technology sectors).

To receive the latest product information, subscribe to our newsletter here

Click below for a video introduction from Professor David Denning.